SCHEMBL20057556

SCHEMBL20057556

CNc1c(Nc2cccc(C)c2)c(=O)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 1/20 0.53
HDAC1 Q13547 1/20 0.51
CXCR2 P25025 3/20 0.49
MAPT P10636 3/20 0.47
HTT P42858 2/20 0.47
ADORA2A P29274 1/20 0.46
HAVCR2 Q8TDQ0 1/20 0.46
MAPKAPK2 P49137 2/20 0.46
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NFKB1 P19838 1/20 0.44
CDC7 O00311 1/20 0.43
PLK4 O00444 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8230052 0.81 ADORA2A (0.53) NPSR1MEN1KMT2APOLBHDAC1
SCHEMBL19956913 0.79 CXCR2 (0.56) MEN1KMT2APOLBCXCR2MAPKAPK2
SCHEMBL20323598 0.78 KMT2A (0.87) MEN1KMT2APOLBMAPTMAPK1
SCHEMBL20057553 0.77 RAPGEF4 (0.50) MEN1KMT2AHDAC1CXCR2MAPT
SCHEMBL19956901 0.77 IDH2 (0.59) MEN1KMT2APOLBMAPTHTT
SCHEMBL1009206 0.76 NPSR1 (0.86) NPSR1MEN1KMT2AMAPTHTT
SCHEMBL29650380 0.76 NPSR1 (0.86) NPSR1MEN1KMT2AMAPTHTT
SCHEMBL1931619 0.75 NPSR1 (0.63) NPSR1MAPTHTTHSD17B10CYP1A2
SCHEMBL29697291 0.74
SCHEMBL9158496 0.74 NPSR1 (0.82) NPSR1MEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof UNIVERSITY OF TSUKUBA (JP) 2019-07-16 US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 US disclosed
EP-3309146-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF University of Tsukuba (JP) 2018-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 NPSR1 3/4885MEN1 2469/4885KMT2A 234/4885
US-10351522-B2 Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof HCRTR2, HCRTR1, NPSR1 NPSR1 3/4885MEN1 2469/4885KMT2A 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.